Press Release: Novartis Fabhalta(R) shows -3-

Iptacopan in Participants With IC-MPGN (APPARENT). Available from:

https://clinicaltrials.gov/study/NCT05755386 Accessed May, 2025.

35. Clinicaltrials.gov. NCT05268289. Study of Efficacy and Safety of LNP023

in Participants With Active Lupus Nephritis Class III-IV, +/ - V.

Available from: https://clinicaltrials.gov/study/NCT05268289 Accessed May,

2025.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

June 12, 2025 02:00 ET (06:00 GMT)